KDM6A directly senses oxygen to control chromatin and cell fate,42 and loss of KDM6A contributes to the malignant phenotype by amplifying PRC2-regulated transcriptional repression in bladder cancer and conferring drug resistance in acute myeloid leukaemia.43,44 In summary, the biological functions associated with tumour hypoxia of the novel gene signature still require further investigation in LUAD. The gene discussed is KDM6A; the disease is acute myeloid leukemia.